
Grünenthal by the numbers
We are an independent, family-owned company with headquarters in Aachen, Germany. We are present in 28 countries with affiliates in Europe, Latin America and the USA.
Pain is widely considered the biggest problem in medicine today: a 2011 market research report indicates that more than 1.5 billion people worldwide suffer from chronic pain,1 more than 21% of who suffer for more than 20 years.2 Adequate treatment is often unavailable or hard to access, and as a specialist business focused on this market niche, we’re determined to tackle this problem.
1 Global Industry Analysts, Inc. (2011) Global Pain Management Market to Reach US$60 Billion by 2015, According to a New Report by Global Industry Analysts, Inc. [Online] Available from: http://www.prweb.com/pdfdownload/8052240.pdf [Accessed 14 April 2018].
2 Langley P.C.: The prevalence, correlates and treatment of pain in the European Union. CMRO. 2011;463-480
Our purpose is to change lives for the better. We believe that change is possible. We invest heavily in innovation, exploring new possibilities to develop smart solutions. Success comes from pioneering treatments that transform patients’ lives for the better. This measure of success drives everything we do.
We focus our R&D activities on pain and have built up our portfolio with projects “Beyond Pain” and medical devices. This diversifies our risks and opens new markets for us.
Grünenthal Pharma Ltd. is a wholly owned subsidiary of Grünenthal GmbH which distributes and markets pain and anti-infective products under an exclusive distribution agreement with Grünenthal GmbH.
Our aim is to create a highly respected Pharmaceutical Company in Ireland through introductions of our own research and development products and acquired brands.
Grünenthal Pharma Limited markets Zydol® (tramadol HCI), Zydol SR®, Ixprim®, Ixprim Effervescent®, Versatis®, Qutenza®, Zomig®, Vimovo®, Nexium®, Palexia Film Coated Tablets® and Palexia SR®.
Our vision is to become the preferred partners for our customers, providers and employees by delivering all that we promise.
We are an independent, family-owned company with headquarters in Aachen, Germany. We are present in 28 countries with affiliates in Europe, Latin America and the USA.
A mix of strong entrepreneurial spirit, close collaboration and outstanding performance define our approach alongside a commitment to diversity and inclusivity.
Innovation is at the heart of everything that we do. It’s the driving force behind new ideas and future therapies.
Imaginative researcher? Unconventional strategist? Forward-thinking go-getter? We would love to hear from you.
We cannot do everything alone, and we have found some excellent partners to share the load. We believe that open collaborations bring together all the expertise that is relevant to develop innovative medicines for patients.
We are on a strong and solid economic growth path. In the last years, we’ve already made great progress in acquiring external assets and companies. We will continue on this path as it allows us to broaden our portfolio and entrepreneurial basis.